FOR IMMEDIATE RELEASE [Covington, KY ~ January 13, 2021]
CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces that their research site was one of the top enrolling sites for the Janssen Pharmaceutical Companies of Johnson & Johnson’s large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735. Johnson & Johnson announced the Phase 3 trial reached full enrollment in December.
“We are proud to be one of the highest enrolling sites on this important trial,” states David Mayleben, PhD, Vice President, Research Site Services at CTI. “This success is a testament to all those involved in this trial, from the researchers to the study participants, who are all working together to find a solution for the COVID-19 pandemic.”
CTI was one of more than 250 study locations around the world involved in the ENSEMBLE clinical trial. The site, located in Cincinnati, OH, screened thousands of potential volunteers and enrolled more than 450 participants into the trial in less than 3 months.
CTI, along with University of Cincinnati, Cincinnati Children's Hospital Medical Center, and others have worked to enroll nearly 1,000 participants across greater Cincinnati in multiple Phase 3 COVID-19 vaccine programs.
"Cincinnati has a long history as a crucial geography for medical advancement, dating back to the development of the Polio vaccine,” remarks Timothy J. Schroeder, Chairman and CEO of CTI. “We are proud of the work of our team and our community that enabled us to once again prove a key resource in the fight to combat a global health crisis.”
CTI is currently part of more than 30 active COVID-19 projects for treatment and prevention. CTI, now in its third decade, is one of the 20 largest CROs in the world with associates in more than 60 countries across six continents. The company was recently named the #1 CRO in the world for quality at the 2020 CRO Leadership Awards, outperforming nearly 30 other recognized CROs from around the world.
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, MENA and Asia-Pacific. For more information visit www.ctifacts.com